R‐High‐CHOP/CHASER/LEED with autologous stem cell transplantation in newly diagnosed mantle cell lymphoma: JCOG0406 STUDY
暂无分享,去创建一个
I. Hanamura | M. Taniwaki | Y. Matsuno | M. Ogura | M. Kurosawa | K. Tobinai | D. Maruyama | N. Uike | K. Ando | K. Tsukasaki | K. Sawada | H. Nagai | K. Ohyashiki | Y. Morishima | T. Hotta | T. Shimoyama | Hirofumi Kobayashi | K. Ohnishi | K. Ohmachi | K. Kumagai | N. Fukuhara | Kazuhito Yamamoto | K. Usuki | N. Tsukamoto | M. Wakabayashi | K. Miyazaki | N. Kobayashi | Y. Yakushijin | K. Nosaka | N. Takayama | Shigeo Nakamura | T. Utsumi | H. Gomyo | S. Nakamura | S. Nakamura
[1] R. Houot,et al. Rituximab after Autologous Stem‐Cell Transplantation in Mantle‐Cell Lymphoma , 2017, The New England journal of medicine.
[2] Sonali M. Smith,et al. RB but not R‐HCVAD is a feasible induction regimen prior to auto‐HCT in frontline MCL: results of SWOG Study S1106 , 2017, British journal of haematology.
[3] A. Rosenwald,et al. Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] Michael E. Williams,et al. Mantle cell lymphoma , 2000, Current treatment options in oncology.
[5] W. Klapper,et al. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network , 2016, The Lancet.
[6] R. Suzuki,et al. Prognostic model for mantle cell lymphoma in the rituximab era: a nationwide study in Japan , 2015, British journal of haematology.
[7] Michael L. Wang,et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. , 2013, The New England journal of medicine.
[8] G. Salles,et al. CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte. , 2013, Blood.
[9] R. Ueda,et al. Phase II study of ABV (doxorubicin with increased dose, bleomycin and vinblastine) therapy in newly diagnosed advanced-stage Hodgkin lymphoma: Japan Clinical Oncology Group study (JCOG9705) , 2013, Leukemia & lymphoma.
[10] F. Angrilli,et al. Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi , 2012, British journal of haematology.
[11] E. Kimby,et al. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. , 2008, Blood.
[12] M. Dreyling,et al. Therapy of mantle cell lymphoma: current standards and future strategies. , 2008, Hematology/oncology clinics of North America.
[13] Y. Oki,et al. Phase II study of a salvage regimen using cyclophosphamide, high‐dose cytarabine, dexamethasone, etoposide, and rituximab in patients with relapsed or refractory B‐cell non‐Hodgkin's lymphoma , 2007, Cancer science.
[14] Sigrid Stroobants,et al. Revised response criteria for malignant lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] Martin Dreyling,et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. , 2006, Blood.
[16] E. Hoster,et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the Germa , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] E. Hoster,et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. , 2004, Blood.
[18] K. Franssila,et al. Primary treatment with autologous stem cell transplantation in mantle cell lymphoma: outcome related to remission pretransplant , 2003, European journal of haematology.
[19] Y. Kagami,et al. Pilot Phase I/II Study of New Salvage Therapy (CHASE) for Refractory or Relapsed Malignant Lymphoma , 2003, International journal of hematology.
[20] J. Gribben,et al. Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] D. Hossfeld. E.S. Jaffe, N.L. Harris, H. Stein, J.W. Vardiman (eds). World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues , 2002 .
[22] A. Pileri,et al. Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion , 2000 .
[23] M. Voso,et al. In vivo depletion of B cells using a combination of high‐dose cytosine arabinoside/mitoxantrone and rituximab for autografting in patients with non‐Hodgkin's lymphoma , 2000, British journal of haematology.
[24] M. Seto,et al. Significance of cyclin D1 overexpression for the diagnosis of mantle cell lymphoma: a clinicopathologic comparison of cyclin D1-positive MCL and cyclin D1-negative MCL-like B-cell lymphoma. , 2000, Blood.
[25] B. Nathwani,et al. A clinical analysis of two indolent lymphoma entities: mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid B-cell subcategories): a Southwest Oncology Group study. , 1995, Blood.
[26] A. Pileri,et al. Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion. , 2000, Blood.